Bellevue Group Portfolio holdings
Bellevue Group is a Swiss asset manager that focuses on healthcare investing, small and mid-cap companies and other growth strategies. Martin Bisang and four other founders started it in 1993, and through its subsidiary Bank am Bellevue it first became a major name in brokerage and block trading on the Swiss market. It sold that bank to Luxembourg's KBL Group in 2019, dropping its private client business and becoming a pure asset manager. In 2016 it bought the German asset manager StarCapital to build its presence in Germany, and in 2023 it launched Bellevue Obesity Solutions, a global equity fund.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene
CELG
|
+$21.7M |
| 2 |
Gilead Sciences
GILD
|
+$21M |
| 3 |
Medtronic
MDT
|
+$20.8M |
| 4 |
Biogen
BIIB
|
+$20.2M |
| 5 |
Amgen
AMGN
|
+$15.3M |
Top Sells
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.12% |
| 2 | Financials | 1.6% |
| 3 | Miscellaneous | 1.28% |
Similar funds
Bellevue Group's Q1 2016 Portfolio in Review
Q1 2016 is the first quarter with a 13F filing on record for Bellevue Group, which disclosed 130 positions worth $551M. Its ten largest holdings account for 31% of the portfolio.
Its largest position is Celgene: 210,550 shares worth $21.1M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, followed by Financials and Miscellaneous.
- Bellevue Group's largest Q1 2016 buy was Celgene: 210,550 shares worth $21.1M.
- Bellevue Group's ten largest holdings make up 31% of its $551M portfolio in Q1 2016.
- Bellevue Group disclosed 130 positions in Q1 2016, its first 13F filing on record.
Based on Bellevue Group's 13F filing for Q1 2016, filed 16 May 2016.